Related Experiment Video
Updated: Jun 26, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Gene expression and angiotropism in primary CNS lymphoma
James L Rubenstein1, Jane Fridlyand, Arthur Shen
1University of California, San Francisco, Division of Hematology/Oncology M1282 Box 1270, 94143, USA. jamesr@medicine.ucsf.edu
Blood
|January 19, 2006
Summary
Primary CNS lymphoma exhibits unique gene expression patterns, including high levels of unfolded protein response (UPR) regulators and oncogenes. Activated STAT6 expression in these brain lymphomas correlates with shorter survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Primary CNS lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma confined to the central nervous system.
- Understanding PCNSL's molecular characteristics is crucial for targeted therapies.
Purpose of the Study:
- To compare gene expression profiles of PCNSL with nodal large B-cell lymphomas.
- To identify molecular distinctions and potential therapeutic targets in PCNSL.
Main Methods:
- cDNA microarray analysis was employed to compare gene expression.
- Immunohistochemistry and Western blotting were used to detect protein expression and activation.
Main Results:
- PCNSL shows distinct gene expression compared to nodal lymphomas, with high expression of unfolded protein response (UPR) regulators (e.g., X-box binding protein 1 [XBP-1]), oncogenes (c-Myc, Pim-1), and apoptosis regulators.
- Interleukin-4 (IL-4) and its signaling mediator STAT6 are expressed by tumor cells and vasculature in PCNSL.
- High expression of activated STAT6 is associated with shorter survival in PCNSL patients treated with methotrexate.
Conclusions:
- PCNSL possesses a unique molecular signature characterized by UPR activation and IL-4 pathway involvement.
- Activated STAT6 may serve as a prognostic marker and potential therapeutic target in PCNSL.
